Search results
Showing 886 to 900 of 1490 results for patients and public
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Awaiting development Reference number: GID-TA11162 Expected publication date: 28 July 2027
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026
Awaiting development Reference number: GID-TA11336 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
In development Reference number: GID-TA11100 Expected publication date: TBC
Awaiting development Reference number: GID-TA11499 Expected publication date: TBC
In development Reference number: GID-TA11516 Expected publication date: 06 May 2027
Evidence-based recommendations on transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula. This involves inserting a catheter through the femoral vein and injecting embolisation liquid to seal the fistula.
Show all sections
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.
In development Reference number: GID-TA11812 Expected publication date: 13 January 2027